Tongue metastasis of cutaneous melanoma: Report of two cases and literature review

Renata-Lucena Markman 1, Giuliano-Augusto-Belizarrio Rosa 2, Leonardo Cardili 3, Luciana-Estevam Simonato 4, Thais-Bianca Brandão 5, Ana-Carolina-Prado Ribeiro 6

1 DDS, MSc, PhD. Oral Diagnosis Department, Semiology Area, Piracicaba Dental School, University of Campinas (UNICAMP), Piracicaba, São Paulo, Brazil. Av. Limeira, 901, Areão, Piracicaba, São Paulo, Brazil.
2 DDS. Dental Oncology Service, Instituto do Câncer do Estado de São Paulo [ICESP], Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo, Brazil.
3 MD, MSc. Pathology Service, Instituto do Câncer do Estado de São Paulo [ICESP], Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo, Brazil.
4 DDS, MSc. Universidade Brasil, Campus Fernandópolis, São Paulo, Brazil. Est. Projetada F-1, s/n – Fazenda Santa Rita, Fernandópolis, São Paulo, Brazil.
5 DDS, MSc, PhD. Dental Oncology Service, Instituto do Câncer do Estado de São Paulo [ICESP], Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo, Brazil.
6 DDS, MSc, PhD. Dental Oncology Service, Instituto do Câncer do Estado de São Paulo [ICESP], Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo, Brazil.

Correspondence:
Instituto do Câncer do Estado de São Paulo [ICESP]
Faculdade de Medicina da Universidade de São Paulo
Dental Oncology Service São Paulo, Brazil
Avenida Doutor Arnaldo, 251, São Paulo - SP, Brasil
CEP: 01246-000
carol_pr@yahoo.com.br

Received: 30/04/2018
Accepted: 06/08/2018

Abstract
Introduction: Malignant metastases to the oral cavity are rare and metastatic melanomas of the tongue are considered exceptionally uncommon, with less than 10 cases published in the English literature so far.
Case reports: Two female patients in the 7th decade of life presented to our dental service with nodules in the tongue. Both patients had multiple metastases at the time of oral diagnosis and primary melanoma originated on the skin. An intra-oral incisional biopsy was performed under local anesthesia and the histopathologic analysis was characterized by the proliferation of atypical epithelioid cells displaying a poorly delimited cytoplasm and hyperchromatic nucleus which contained eosinophilic macronucleoli. Immunohistochemistry was performed in both cases to confirm the clinical hypothesis of metastatic melanoma. After the diagnosis of oral metastatic melanoma, the patients were maintained under palliative care and close medical follow-up. Both patients died four and a half months and 20 months after the diagnosis of tongue metastasis.
Conclusions: Although rare, metastatic melanoma should be included in the differential diagnosis of tongue lesions detected in patients with a previous medical history of cutaneous melanoma.

Key words: Melanoma, tongue, metástases.
Introduction
Melanomas are malignant tumors that originate from skin melanocytes and are considered one of the most aggressive types of cancer. Once considered a rare tumor, the incidence of cutaneous melanoma is estimated to be increasing worldwide and usually affects young adults. Solar UV radiation is a well-established risk factor for melanoma, as the most frequently affected sites include sun-exposed areas of fair-skinned patients, such as the dorsal surface of the trunk of the body, arms, legs and the head and neck region. Late diagnosis is often associated with advanced disease characterized by dissemination to regional lymph nodes and distant metastases, leading to a five-year survival rate of 5%. Surgical treatment combined with radiotherapy, chemotherapy and molecular targeted therapy have been used in the treatment of melanoma (1-3).

Primary oral melanomas account for approximately 1% of all cases; the most commonly affected intraoral sites are the palate and the maxillary gingiva. Similarly, oral metastases derived from primary melanomas located at distant sites are considered extremely rare (4). In this scenario, only eight cases of metastatic melanoma of the tongue have been reported in the English literature so far (Table 1). Therefore, the aim of this article was to report two new cases of primary cutaneous melanoma metastasizing to the tongue and to further review the current knowledge regarding melanoma metastases to the oral cavity and tongue.

Case Report
Case 1
A 62-year-old female patient was referred by her oncologist for a routine dental evaluation. The patient’s medical history revealed a cutaneous melanoma of the left dorsum diagnosed six years before she was referred to our dental service. The tumor was primarily treated by surgery and developed two local recurrences (one and three years following surgery, respectively), which were also managed by surgical resection. Disease progression was identified five years after the first treatment and confirmed by a computed tomography (CT), which revealed multiple organ involvement including the lungs, skin (subcutaneous nodules on the dorsum) and bone (osteolytic lesions in the iliac and femur bones, ribs, vertebrae, sternum and scapula).

The patient was undergoing a palliative treatment protocol based on dacarbazine, zoledronic acid and radiotherapy in the lumbar region (total dose of 20 Gy) and in the left supraventricular fossa (total dose of 36 Gy) when she was referred to our dental facility. An extraoral clinical examination identified a pigmented subcutaneous nodule on the patient’s dorsum, measuring 5 cm in diameter, and scarring from the previous surgical resections.

The patient’s chief complaint was the loss of the dental crown of her upper left incisor. She denied oral pain or the existence of any relevant oral soft tissue lesion. Intraoral soft tissue examination revealed a nodule with an ulcerated surface and areas of telangiectasia, on the

Table 1: Literature review of 8 cases of melanoma metastatic to the tongue.

<table>
<thead>
<tr>
<th>Case</th>
<th>Author</th>
<th>Sex</th>
<th>Age</th>
<th>Primary site</th>
<th>Metastases</th>
<th>Treatment</th>
<th>Time from primary tumor to tongue metastasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Zegarelli et al, 1973(5)</td>
<td>M</td>
<td>47</td>
<td>Skin</td>
<td>Tongue, Lung, skin and liver</td>
<td>Unknown</td>
<td>2.5 yrs</td>
</tr>
<tr>
<td>2</td>
<td>Patton et al, 1994(1)</td>
<td>F</td>
<td>26</td>
<td>Skin</td>
<td>Tongue</td>
<td>P surgical resection CHT and IMT, R AxND</td>
<td>4 yrs</td>
</tr>
<tr>
<td>3</td>
<td>Patton et al, 1994(1)</td>
<td>M</td>
<td>27</td>
<td>Skin</td>
<td>Tongue</td>
<td>P surgical resection CHT and IMT, R RND</td>
<td>8.1 yrs</td>
</tr>
<tr>
<td>4</td>
<td>Patton et al, 1994(1)</td>
<td>F</td>
<td>47</td>
<td>Skin</td>
<td>Tongue</td>
<td>P surgical resection CHT, R RND</td>
<td>4.5 yrs</td>
</tr>
<tr>
<td>5</td>
<td>Patton et al, 1994(1)</td>
<td>M</td>
<td>51</td>
<td>Skin</td>
<td>Tongue</td>
<td>P and ORL surgical resection, P CHT, ORL RT</td>
<td>6 yrs</td>
</tr>
<tr>
<td>6</td>
<td>Patton et al, 1994(1)</td>
<td>F</td>
<td>52</td>
<td>Skin</td>
<td>Tongue</td>
<td>P surgical resection, P CHT</td>
<td>3.2 yrs</td>
</tr>
<tr>
<td>7</td>
<td>Alvès et al, 1994(6)</td>
<td>M</td>
<td>72</td>
<td>Skin</td>
<td>Tongue</td>
<td>P and ORL surgical resection, IngND</td>
<td>1.25 yrs</td>
</tr>
<tr>
<td>8</td>
<td>Tai et al, 2015(7)</td>
<td>F</td>
<td>79</td>
<td>Skin</td>
<td>Tongue, Skin, subcutaneous and muscular tissues and lymph nodes.</td>
<td>P surgical resection, IngND, P CHT and IMT, palliative CHT and ORL RT</td>
<td>10 yrs</td>
</tr>
<tr>
<td>9</td>
<td>Case 1, 2018</td>
<td>F</td>
<td>62</td>
<td>Skin</td>
<td>Tongue, dorsum, osteolytic lesions in the iliac and femur bones, ribs, vertebrae, sternum, scapula and lungs.</td>
<td>P and ORL surgical resection, palliative CHT</td>
<td>6 yrs</td>
</tr>
<tr>
<td>10</td>
<td>Case 2, 2018</td>
<td>F</td>
<td>62</td>
<td>Skin</td>
<td>Tongue, subcutaneous mass, retroperitoneal region and central nervous system.</td>
<td>P and ORL surgical resection, palliative CHT</td>
<td>4 yrs</td>
</tr>
</tbody>
</table>

CHT, Chemotherapy; P, Primary tumor; ORL, Oral metastasis; B, Bilateral; AxND, Axillary node dissection; RND, Radical neck dissection; RT, Radiotherapy; IMT, Immunotherapy; R, Right; AxND, Axillary node dissection; IngND, Inguinal node dissection.
Tongue metastasis of cutaneous melanoma


An incisional biopsy was performed under local anesthesia. The histopathological analysis showed nests and solid sheets of non-pigmented atypical cells with an epithelioid phenotype infiltrating the sub-epithelial connective tissue. A high mitotic index was observed (Fig. 1B). Tumor cells displayed diffuse immnostaining for S100 protein. Other melanocytic markers such as HMB-45 and Melan-A were negative. (Fig. 1C).

After the diagnosis of a metastatic lesion on the tongue, the patient was referred back to the clinical oncologist who maintained her in a palliative protocol of chemotherapy with cisplatin, dacarbazine and vinblastine (CVD). Unfortunately, the patient died due to disease progression four and a half months after the diagnosis of tongue metastasis.

Case 2

A 62-year-old female was diagnosed with an acral lentiginous melanoma on the right heel four years previously. At that time, CT revealed pulmonary nodules and the patient was kept in close follow-up. Two years after the initial diagnosis, the patient was submitted to a pulmonary biopsy with a diagnosis of metastatic melanoma. Four months later, the patient requested a dental evaluation due to a fast-growing submucosal nodular lesion on her tongue. During the first dental appointment, intraoral soft tissue examination revealed a submucosal nodule in the right dorsum of the tongue measuring approximately 2 cm in diameter and firm upon palpation (Fig. 2A). The patient reported three months of painless nodule progression. Based on the previous medical history of the patient, the diagnostic hypothesis included metastatic melanoma and benign mesenchymal neoplasm.

An intra-oral incisional biopsy was performed under local anaesthesia. The histopathologic analysis was characterized by proliferation of atypical epithelioid cells displaying a poorly delimited cytoplasm and hyperchromatic nucleus which contained eosinophilic macronucleoli (Fig. 2B). Immunohistochemistry showed multifocal staining for melanocytic markers, including S100 (Fig. 2C), HMB-45 (Fig. 2D) and Melan-A (Fig. 2E). These findings confirmed the clinical hypothesis of metastatic melanoma.

After diagnosis, the patient was referred back to the clinical oncologist who investigated a left subclavicular mass with a diagnosis of metastatic melanoma and also presented disease progression to the lungs, retroperitoneal region and central nervous system. The patient died 20 months after the diagnosis of oral metastatic melanoma even though she was under palliative care and careful medical follow-up.

Discussion

The oral region is an uncommon site for metastatic tumor cell colonization. Still, there are many reported cases of oral metastases being the first indication of undiscovered malignancies. In the oral soft tissues, the attached gingiva seems to be the most common site for metastatic colonization and it usually resembles a hyperplastic or reactive lesion, such as pyogenic granuloma, peripheral giant cell granuloma, or fibrous epulis. In locations other than the gingiva, it may present as a submucosal mass(8), as seen in case 2. Both cases of metastatic melanoma described in this report had primary tumors of the skin and one of them was a clinical finding during a dental assessment. A gap of several years between the time of treatment of primary...
Tongue metastasis of cutaneous melanoma

A consensus is lacking on treatment for metastatic melanoma. Systemic therapy is based on many chemotherapeutic protocols; however, these have been used with varying success and little improvement in median survival. Immunomodulatory agents are also used but have low response rates, many side effects and are not recommended for all patients (11). Hope relies in targeted agents such as ipilimumab and vemurafenib, which are revolutionizing the treatment of metastatic melanoma (12,13). Both patients in our report had many metastatic lesions and were treated by palliative protocols due to the inability to control disease progression. The prognosis in these cases is often very bad, and both patients died after 4 and a half and 20 months respectively.

Melanomas can histologically mimic a wide variety of neoplasms, including poorly differentiated carcinomas, high-grade lymphomas and even round cell sarcomas (6). Besides the epithelioid phenotype, the intracytoplasmic melanin deposits and eosinophilic macronucleolus are the most reliable histomorphological clues to melanoma diagnosis. However, some cases do not show the usual features and may represent a challenge for the precise microscopic detection. In the metastatic disease, it is not uncommon to see amelanotic lesions, probably due to the selection of poorly differentiated tumor cell clones. In addition, not only the pigment can be lesse-
ned or even absent but also the nuclear features and/or the cytoplasmic conformation. Spindle cell melanomas may be difficult to distinguish from round cell sarcomas, sarcomatoid carcinomas, or even an inflammatory scarring process (14). Small cell tumor phenotype includes other differential diagnoses, such as lymphoproliferative diseases and round cell sarcomas. In such settings, immunohistochemistry represent a highly valuable diagnostic tool. The most useful melanocytic-related markers are S100 protein, HMB-45 and Melan-A (also known as MART-1). All of them are expected to be positive in melanocytic neoplasms, even though their sensitivity and specificity may vary, with S100 protein being regarded as the most sensitive and HMB-45 and Melan-A as the most specific. This consistent melanocytic profile should be associated to negative immunostaining for other malignancies coming from the histomorphological analysis, such as lymphoid markers (CD45, CD20, CD3), epithelial markers (cytokeratins, epithelial membrane antigen, BER-EP4), mesenchimal markers (WT-1, CD99, desmin, muscle actins) and neuroendocrine markers (sinaptophysine, cromogranin), among others.

Conclusion
Tongue metastases of melanoma are rare and are associated with widespread disease and consequently poor prognosis and low survival rates, as seen in the cases described here. Health professionals should always give importance to the patient’s medical history and perform a systematic oral examination to provide an early diagnosis to improve treatment and survival. Finally, metastatic tumors should always be included in the differential diagnosis of oral lesions in patients with a previous medical history of cancer.

References
9. Kämmerer PW, Shahazfar N, Palarie V, Kleis W, Al-Nawas B. The-